NMRA-511 Updated Sep 13
Watch for NMRA-511 MAD expansion cohort data in Q4 2026, positive results could drive a significant rally given the stock's ~$1.04 price and 380% implied analyst upside, but negative data would pressure shares. The company has multiple shots on goal (navacaprant, NMRA-898, NMRA-215), so NMRA-511 is not a single-point-of-failure.
- Phase 1b data showed encouraging efficacy signals: Cohen's d effect size of 0.34 on CMAI total score and 0.51 on aggression sub-factor in Alzheimer's agitation patients, suggesting meaningful clinical benefit.
- Massive institutional accumulation in Q2 2026: BlackRock doubled its position (+279%), Geode doubled (+140%), Citadel doubled (+141%), and many other funds added or doubled positions, signaling institutional confidence.
- Analyst consensus is strongly bullish: 12 Buy/Strong Buy ratings vs. 2 Hold and 1 Sell, with a mean price target of $6.14 implying ~380% upside from the current ~$1.04 price.
- Phase 1b data is early and Cohen's d effect sizes from small studies often fail to replicate in larger, placebo-controlled Phase 2/3 trials, the 0.34-0.51 range may shrink or disappear.
- Insider selling: COO Daljit Singh Aurora sold ~$500K+ worth of shares in mid-August 2026 at ~$1.50-1.65, well above the current ~$1.04 price, signaling insider caution.
- The company is pre-revenue with a $43.1M quarterly net loss and $116.8M cash, at the current ~$33M quarterly burn rate, a capital raise may be needed by late 2027, causing dilution.